Search
Ceftaroline fosamil
go.drugbank.com/drugs/DB06590ApprovedInvestigationalCeftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalPhiladelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein. … Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFlupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market. … Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigationalIt has a significant impact on both the physical and social functioning of affected individuals. … Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss.
Products: BETAHISTIN AL 6, BETAHISTIN AL 12Desvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … [A261271] Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine].
Gadobutrol
go.drugbank.com/drugs/DB06703ApprovedInvestigationalDue to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. … Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age.
Categories: Compounds used in a research, industrial, or household settingMethacholine
go.drugbank.com/drugs/DB06709Approved[L31763] In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR. … [A229603, A229618, A229643] Methacholine is a non-specific cholinergic agonist (parasympathomimetic) that acts through muscarinic receptors in the lungs to induce bronchoconstriction.
Naphazoline
go.drugbank.com/drugs/DB06711ApprovedNaphazoline was first developed in 1942 as a nasal formulation for congestion[A176609]. … Naphazoline is a rapid acting imidazoline sympathomimetic vasoconstrictor of ocular or nasal artierioles[L5804,L5807].
Mixtures: Opcon-A, Naphcon A